Boehringer Ingelheim
For Healthcare Professionals

PF360_Desktop_banner

Interstitial lung diseases (ILDs) make up a diverse group of more than 200 heterogeneous lung disorders, many classified as rare.1,5,6 Despite being infrequently seen in practice, ILDs collectively affect a considerable number of patients and represent a substantial burden of disease.7 A wide range of these ILDs are characterized by pulmonary fibrosis, which can become a key driver of irreversible lung damage and early mortality.1-4

Pulmonary fibrosis is a common and critical threat across a broad range of fibrotic ILDs, warranting urgent identification and timely intervention.1-4

Choose your specialty below and click to learn more:

Learn more
Pulmonologists

Pulmonologists

Irrespective of lung injury trigger, progressive fibrosing ILDs show commonalities in the pathogenic mechanisms that drive the fibrotic process.8,9
Learn more
See your role
Multidisciplinary care team

Multidisciplinary care team

Radiologists, pulmonary nurses, and primary care physicians have vital roles to play in the early identification and effective management of pulmonary fibrosis.
See your role

CTD-ILD, connective tissue disease-associated interstitial lung disease; RA, rheumatoid arthritis; SARD, systemic autoimmune rheumatic disease; SARD-ILD, systemic autoimmune rheumatic disease-associated interstitial lung disease; SSc, systemic sclerosis.

  • 1.
     Flaherty KR, Brown KK, Wells AU, et al. Design of the PF-ILD trial: A double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease. BMJ Open Resp Res. 2017;4(1):e000212.
  • 2.
     Patterson KC, Strek ME. Pulmonary fibrosis in sarcoidosis. Clinical features and outcomes. Ann Am Thorac Soc. 2013;10(4):362-370.
  • 3.
     Caban JJ, Yao J, Bagci U, Mollura DJ. Monitoring pulmonary fibrosis by fusing clinical, physiological, and computed tomography features. Conf Proc IEEE Eng Med Biol Soc. 2011;6216-6219.
  • 4.
     Wells AU, Brown KK, Flaherty KR, Kolb M, Thannickal VJ, on behalf of the IPF Consensus Working Group. Eur Resp J. 2018;51:1800692.
  • 5.
     Cottin V, Hirani N, Hotchkin D, et al. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018;27(150):180076. 
  • 6.
     Demedts M, Wells AU, AntÓ JM, et al. Interstitial lung diseases: an epidemiological overview. Eur Respir J Suppl. 2001;18(suppl32):2s-16s.
  • 7.
     Wijsenbeek M, Cottin V. Spectrum of fibrotic lung diseases. N Engl J Med. 2020;383:958-968.
  • 8.
     Wuyts WA, Agostini C, Antoniou KM, et al. The pathogenesis of pulmonary fibrosis: a moving target. Eur Respir J. 2013;41(5):1207-1218.
  • 9.
    Maher TM, Wuyts W. Management of fibrosing interstitial lung diseases. Adv Ther. 2019;36(7):1518-1531.